ArticleClinical kidney journal2025
Size-selective glomerular filtration as a hallmark of premature kidney ageing in nondiabetic individuals.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selective glomerular hypofiltration syndrome: a novel renal phenotype associated with cardiovascular disease and adverse outcomes in diabetic kidney disease.BMJ open diabetes research & care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: During the last decade, evidence has emerged on selective glomerular hypofiltration syndromes (SGHS), defined by selectively reduced filtration of middle-sized molecules irrespective of kidney function and resulting in a low ratio between cystatin C- and creatinine-based estimated glomerular filtration rates (eGFRcys/eGFRcr). We aimed to examine whether SGHS is a hallmark of premature kidney ageing manifested by accumulation of advanced glycation end-products (AGEs) and endothelial dysfunction in a population free from chronic kidney disease and diabetes. Methods: A total of 3804 participants of The Malmö Offspring Study (MOS) underwent AGE (skin autofluorescence acquired), eGFRcys and eGFRcr measurements. AGEs ≥1.6 were categorized as high, and AGEs <1.6 as normal. Reactive hyperemia index (RHI) was available in 2204 participants; RHI <1.67 indicated endothelial dysfunction (ED), and RHI ≥1.67 normal endothelial function (EF). Combining AGEs and RHI, four groups were compared: (group 1) AGEs <1.6 and EF, (group 2) AGEs <1.6 and ED, (group 3) AGEs ≥1.6 and EF, and (group 4) AGEs ≥1.6 and ED. Results: Lower eGFRcys/eGFRcr ratio was associated with an increase in AGEs in men and women. After adjusting for cardiovascular factors, lower eGFRcys/eGFRcr ratio was associated with AGE accumulation in men older than 30 years. The 'AGEs ≥1.6 and ED' and 'AGEs ≥1.6 and EF' groups showed the highest prevalence of eGFRcys/eGFRcr under 0.9 (in men, 22% vs 19.7%, in women 19.5% vs 16%, respectively). Conclusions: Accumulation of AGEs resulting from SGHS leads to age dependent changes in glomerular basement membrane and increased selectivity for middle-sized molecules. Presence of these findings in younger individuals supports the hypothesis that SGHS is a model of early kidney ageing, occurring before decline in kidney function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.